CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

CombiMatrix Corp CBMX: Granted approval for pre-implantation genetic screening and conditional approval from NYS Department of Health.

CytRx Corporation CYTR: Announced Aldoxorubicin achieved primary endpoint, stating, “Statistically significant improvement in progression-free survival in patients with Liposarcoma." The company expects to submit an NDA with the FDA for Aldoxorubicin as treatment for patients with relapsed or refractory STS in 2017.

Dimension Therapeutics Inc DMTX Received positive opinion for DTX401 for European orphan drug designation.

KemPharm Inc KMPH: Received FDA clearance to initiate KP201/IR trial.

Momenta Pharmaceuticals, Inc. MNTA: Announced Phase III for M923 met primary endpoint and all secondary endpoints.

Novan Inc NOVN: Announced Phase II trial achieved significant results.

Vascular Biogenics Ltd VBLT:

Announced VB-111 met primary endpoint, stating, "[It] shows evidence of overall survival rate."All data compiled using Benzinga Pro.

Market News and Data brought to you by Benzinga APIs